$UPB News

HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio Presents New Data From Phase 2 VIBRANT Trial Evaluating Verekitug In Participants With Chronic Rhinosinusitis With Nasal Polyps At ATS 2026 International Conference

Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18

Upstream Bio shares are trading lower after Evercore ISI Group downgraded the stock from Outperform to In-Line and lowered its price target from $40 to $15.

Upstream Bio shares are trading lower after Evercore ISI Group downgraded the stock from Outperform to In-Line and lowered its price target from $40 to $15.

Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Plans To Initiate Dosing In Phase 3 Trials In Both Severe Asthma And CRSwNP In Q1 2027

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio Phase 2 VIBRANT Data Showed Primary Endpoint Of Endoscopic Nasal Polyp Score Showed Reduction Of -1.95 (p < 0.0001); Secondary Endpoints Also Provided Strong Efficacy Data In New Analyses

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Peering Into Upstream Bio Inc's Recent Short Interest

Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%